SLC25A1: A Protein Involved in Ion Channels and Neurotransmission

Target Name: SLC25A1

NCBI ID: G6576

SLC25A1

SLC25A1: A Protein Involved in Ion Channels and Neurotransmission

SLC25A1 (PmCiC) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its function is not well understood, but it is known to play a role in the regulation of ion channels and neurotransmitter release.

One of the unique features of SLC25A1 is its structure. It is a member of the superfamily of inner mitochondrial transport proteins (SMITP), which are known for their ability to transport small molecules across the mitochondrial membrane. SLC25A1 has a unique combination of amino acids that give it a distinct 3D structure, with a long, linear molecule that has a positively charged carboxylic acid side and a negatively charged phosphate side.

SLC25A1 is also known for its ability to interact with other proteins. Studies have shown that SLC25A1 can form interactions with a variety of different proteins, including ion channels, neurotransmitters, and transcription factors. These interactions may be important for the regulation of various cellular processes , including neurotransmission and ion channel function.

One of the potential applications of SLC25A1 as a drug target is its ability to modulate the activity of ion channels. Ion channels are critical for the regulation of various physiological processes, including muscle contractions, nerve impulses, and brain function. Alterations in ion channel activity can have a significant impact on cellular behavior, and may be involved in a wide range of diseases, including neurodegenerative disorders, epilepsy, and cardiovascular disease.

SLC25A1 has been shown to play a role in modulating the activity of ion channels in various cellular contexts. For example, studies have shown that SLC25A1 can inhibit the activity of Na+ channels, which are involved in neurotransmission and muscle contractions. This may have implications for the treatment of certain neurological disorders, such as epilepsy and migraine.

In addition to its potential as a drug target, SLC25A1 is also a potential biomarker for various diseases. The regulation of ion channels is a critical aspect of cellular physiology, and alterations in ion channel activity can be indicative of a wide range of cellular processes, including disease. Therefore, SLC25A1 may be a useful biomarker for various neurological and cardiovascular disorders.

SLC25A1 has also been shown to play a role in the regulation of cellular metabolism and homeostasis. Ion channels are involved in the regulation of intracellular ion concentration, which is critical for maintaining cellular homeostasis. Therefore, alterations in ion channel activity can have a significant impact on cellular metabolism and homeostasis.

In conclusion, SLC25A1 is a protein that is expressed in various tissues of the body and is known to play a role in the regulation of ion channels and neurotransmission. Its unique structure and ability to interact with other proteins make it an attractive candidate as a drug target and biomarker for various neurological and cardiovascular disorders. Further research is needed to fully understand the function of SLC25A1 and its potential as a therapeutic agent.

Protein Name: Solute Carrier Family 25 Member 1

Functions: Mitochondrial electroneutral antiporter that exports citrate from the mitochondria into the cytosol in exchange for malate (PubMed:29031613, PubMed:29238895). Also able to mediate the exchange of citrate for isocitrate, phosphoenolpyruvate, cis-aconitate and to a lesser extend cis-aconitate, maleate and succinate (PubMed:29031613). In the cytoplasm citrate is important in the regulation of glycolysis through a feedback mechanism and in the production of acetyl-CoA which is needed for the synthesis of fatty acids, sterols, prostaglandins, dolichol and coenzyme Q (CoQ). Required for proper neuromuscular junction formation (Probable)

The "SLC25A1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC25A1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets